Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FOS | P01100 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 2/20 | 0.39 |
| ▸ | CDK8 | P49336 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8373632 | 0.91 | ALDH1A1 (0.52) | ALDH1A1SYKMAPTSMN1; SMN2LMNA | |
| SCHEMBL4714245 | 0.89 | ALDH1A1 (0.46) | ALDH1A1SYKMAPTSMN1; SMN2LMNA | |
| SCHEMBL10192488 | 0.89 | ALDH1A1 (0.46) | ALDH1A1SYKMAPTSMN1; SMN2LMNA | |
| SCHEMBL7795394 | 0.88 | ALDH1A1 (0.44) | ALDH1A1SYKMAPTSMN1; SMN2LMNA | |
| SCHEMBL4713326 | 0.85 | ALDH1A1 (0.41) | ALDH1A1SYKMAPTSMN1; SMN2LMNA | |
| SCHEMBL4715139 | 0.84 | ALDH1A1 (0.43) | ALDH1A1SYKMAPTSMN1; SMN2LMNA | |
| SCHEMBL4711389 | 0.84 | ALDH1A1 (0.43) | ALDH1A1SYKMAPTSMN1; SMN2LMNA | |
| SCHEMBL5264290 | 0.83 | HTT (0.46) | ALDH1A1SYKMAPTSMN1; SMN2LMNA | |
| SCHEMBL4714331 | 0.83 | SYK (0.53) | ALDH1A1SYKMAPTSMN1; SMN2LMNA | |
| SCHEMBL23266642 | 0.82 | MEN1 (0.44) | ALDH1A1SYKMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0964864-B1 | PYRIDO 2,3-D PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-04-09 | — | — | EP | claimed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | claimed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0964864-B1 | PYRIDO 2,3-D PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1806348-A2 | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | ALDH1A1 1162/4885SYK 2342/4885MAPT 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.